VENLO, The Netherlands, Sept. 21, 2004 (PRIMEZONE) -- QIAGEN N.V. (Nasdaq:QGENF) (Frankfurt, Prime Standard:QIA) today announced that it will present at the UBS Global Life Sciences Conference at 8:30 a.m. EDT on Tuesday, September 28, 2004. The conference is being held at The Grand Hyatt New York, Park Avenue at Grand Central in New York City.
Peer M. Schatz, QIAGEN's Chief Executive Officer and Roland Sackers, QIAGEN's Chief Financial Officer, will provide an overview of the company, discuss QIAGEN's business as well as recent developments and outline future opportunities. QIAGEN's presentation will be audio webcasted for investors live and by replay until October 30, 2004 and available at http://www.ibb.ubs.com. The corresponding presentation slides can be accessed in the Investor Relations section at http://www.qiagen.com.
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).
Peer M. Schatz Chief Executive Officer QIAGEN N.V. +49 2103 2911 702 e-mail: peer.schatz@QIAGEN.com
Dr. Solveigh Mahler Director of Investor Relations QIAGEN N.V. +49 2103 2911 710 e-mail: solveigh.maehler@QIAGEN.com